Negi S, Yamanaka M, Sugiyama I, Komatsu Y, Sasho M, Tsuruoka A, Kamada A, Tsukada I, Hiruma R, Katsu K
Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan.
J Antibiot (Tokyo). 1994 Dec;47(12):1507-25. doi: 10.7164/antibiotics.47.1507.
The synthesis and antibacterial activities of 7 beta-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-N,N - dimethylcarbamoyloxymethyl-3-cephem-4-carboxylic acid (E1100) and its analogs are described, as well as oral absorbability and in vivo activities of the 1-(isopropoxycarbonyloxy)ethyl ester (E1101) and its analogous esters. The introduction of acyclic and cyclic lower alkyl groups at the N-position of 3-carbamoyloxymethyl cephems influences antibacterial activities, especially against H. influenzae, and oral absorbability of their prodrug esters. The structure-activity relationships are also discussed.
描述了7β-[2-(2-氨基噻唑-4-基)-2-羟基亚氨基乙酰胺基]-3-N,N-二甲基氨甲酰氧基甲基-3-头孢烯-4-羧酸(E1100)及其类似物的合成与抗菌活性,以及1-(异丙氧基羰氧基)乙酯(E1101)及其类似酯的口服吸收性和体内活性。在3-氨甲酰氧基甲基头孢烯的N位引入无环和环状低级烷基会影响抗菌活性,尤其是对流感嗜血杆菌的活性,以及其前药酯的口服吸收性。还讨论了构效关系。